JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

Начало・Списък с акции・Eli Lilly and Co.

Search

Eli Lilly and Co.

Затворен

СекторЗдравеопазване

1,130.08 0.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1124.16

Максимум

1165.57

Ключови измерители
By Trading Economics
Приходи	758M 7.4B
Продажби	507M 20B
P/E Средно за сектора	38.458 49.888
EPS	8.55
Дивидентна доходност	0.56
Марж на печалбата	37.355
Служители	50,000
EBITDA	971M 9.4B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+17.5% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.56% 2.38%
Следващи печалби	5.08.2026 г.
Следваща дата на дивидент	10.06.2026 г.
Следваща дата на екс-дивидент	14.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	189B 965B
Предишно отваряне	1129.64
Предишно затваряне	1130.08

Настроения в новините

By Acuity

35%

65%

108 / 344 Класиране в Healthcare

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2026 г., 14:24 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Buys Engage Biologics for Up to $202 Million

2.06.2026 г., 04:01 ч. UTC

Придобивния, сливания и поглъщания

M&A Is Back in a Big Way. These Are the Sectors in Play. -- Barrons.com

29.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

26.05.2026 г., 12:29 ч. UTC

Придобивния, сливания и поглъщания

Lilly Agrees to Buy Trio of Vaccine Developers -- Update

26.05.2026 г., 10:35 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Agrees to Acquire Three Vaccine Developers, Company Says -- WSJ

26.05.2026 г., 10:35 ч. UTC

Придобивния, сливания и поглъщания

Lilly's Deals Are Worth up to Nearly $4 Billion Combined, Company Says -- WSJ

26.05.2026 г., 10:35 ч. UTC

Придобивния, сливания и поглъщания

Lilly to Acquire Curevo, LimmaTech and Vaccine Co., Company Says -- WSJ

26.05.2026 г., 10:35 ч. UTC

Придобивния, сливания и поглъщания

Lilly Agrees to Buy Trio of Vaccine Developers -- WSJ

20.05.2026 г., 13:35 ч. UTC

Придобивния, сливания и поглъщания

Engage Bio: Eli Lilly Deal Includes Upfront, Milestone Payments >LLY

20.05.2026 г., 13:34 ч. UTC

Придобивния, сливания и поглъщания

Engage Bio Acquired by Eli Lilly for Up to $202 Million >LLY

7.05.2026 г., 09:30 ч. UTC

Печалби

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6.05.2026 г., 12:36 ч. UTC

Печалби

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6.05.2026 г., 10:12 ч. UTC

Печалби

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6.05.2026 г., 09:58 ч. UTC

Печалби

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30.04.2026 г., 20:59 ч. UTC

Горещи акции

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30.04.2026 г., 20:12 ч. UTC

Печалби

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 16:43 ч. UTC

Печалби

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30.04.2026 г., 16:10 ч. UTC

Пазарно говорене

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30.04.2026 г., 15:13 ч. UTC

Печалби

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 14:58 ч. UTC

Печалби

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30.04.2026 г., 14:53 ч. UTC

Печалби

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30.04.2026 г., 14:50 ч. UTC

Печалби

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30.04.2026 г., 14:42 ч. UTC

Печалби

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30.04.2026 г., 14:39 ч. UTC

Печалби

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30.04.2026 г., 14:35 ч. UTC

Печалби

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30.04.2026 г., 14:24 ч. UTC

Печалби

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30.04.2026 г., 14:17 ч. UTC

Печалби

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30.04.2026 г., 13:56 ч. UTC

Печалби

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 13:37 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30.04.2026 г., 12:32 ч. UTC

Пазарно говорене

Печалби

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

17.5% нагоре

12-месечна прогноза

Среден 1,267.57 USD 17.5%

Висок 1,500 USD

Нисък 850 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

23 ratings

20

Купи

2

Задържане

1

Продай

Според 23 анализатори, дали борсови рейтинги на Eli Lilly and Co. през последните 3 месеца.

Настроение

By Acuity

108 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Други акции от сектора

JNJ

Johnson and Johnson

232.65

ABBV

AbbVie Inc

227.34

UNH

UnitedHealth Group Inc

400.31

MRK

Merck & Co Inc.

120.93

AZN

AstraZeneca PLC

185.95

Live chat